TP53 and cancer: In several cancer types, including breast cancer, cervical cancer, endometrial cancer, colorectal cancer, gastric cancer, and ovarian cancer, higher expression of miR-665 is associated with a decline in patient survival time (based on data from the TCGA database and Kaplan–Meier analysis), and miR-665 in these cases inhibits tumor suppressor genes, like TP53, APC, and BRCA1.